Pharmacokinetics of αIFN-2b in chronic hepatitis C virus patients undergoing chronic hemodialysis or with normal renal function: Clinical implications

Journal of the American Society of Nephrology

Volumn 9, Issue 12, 1998, Pages 2344-2348

  Rostaing, Lionel ^a,c   Chatelut, Etienne ^b   Payen, Jean Louis ^a   Izopet, Jacques ^a   Thalamas, Claire ^a   Ton That, Hugues ^a   Pascal, Jean Pierre ^a   Durand, Dominique ^a   Canal, Pierre ^b  

^a TOULOUSE UNIVERSITY HOSPITAL   (France)

^b INSTITUT CLAUDIUS REGAUD   (France)

^c CHU RANGUEIL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT ERYTHROPOIETIN; ALPHA2B INTERFERON; ANTIVIRUS AGENT;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DRUG BLOOD LEVEL; DRUG HALF LIFE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART ARRHYTHMIA; HEMODIALYSIS; HEPATITIS C; HUMAN; LONG TERM CARE; LUNG FIBROSIS; MALE; NEUROTOXICITY; PHARMACOKINETICS; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; UREMIA; CHRONIC KIDNEY FAILURE; COMPARATIVE STUDY; KIDNEY FUNCTION TEST; METABOLIC CLEARANCE RATE; METABOLISM; MIDDLE AGED; PROSPECTIVE STUDY; RENAL REPLACEMENT THERAPY; VIREMIA;

ADULT; AGED; ANTIVIRAL AGENTS; AREA UNDER CURVE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERFERON ALFA-2B; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; PROSPECTIVE STUDIES; RENAL DIALYSIS; VIREMIA;

EID: 0031593545     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Pereira BJ, Levey AS: Hepatitis C virus infection in dialysis and renal transplantation. Kidney Int 51: 981-999, 1997
2. Stuyver L, Claeys H, Wyseur A, van Arnhem W, de Beenhouwer H, Uytendaele S, Beckers J, Matthijs D, Leroux-Roels G, Maertens G, de Paepe M: Hepatitis C virus infection in a hemodialysis unit: Molecular evidence for nosocomial transmission. Kidney Int 49: 889-895, 1996
3. Payen JL: Surveillance d'une hépatite chronique virale C traitée ou non traitée. Gastroenterol Clin Biol 20: S167-S174, 1997
4. Pereira BJ, Wright TL, Schmid CH, Levey AS: The impact of pretransplantation hepatitis C virus infection on the outcome of renal transplantation. Transplantation 60: 799-805, 1995
5. Koenig P, Vogel W, Umlauft F, Weyrer K, Prommegger R, Lhotta K, Neyer U, Stummvoll HK, Gruenewald K: Interferon treatment for chronic hepatitis C virus infection in uremic patients. Kidney Int 45: 1507-1509, 1994
6. Izopet J, Rostaing L, Moussion F, Alric L, Dubois M, Ton That H, Payen JL, Duffaut M, Durand D, Suc JM, Puel J. High rate of HCV RNA clearance in hemodialysis patients after alpha-interferon therapy. J Infect Dis 176: 1614-1617, 1997
7. Gutterman JV, Fine S, Quesada J, Horning SJ, Levine JF, Alexanian R, Bernhardt L, Kramer M, Spiegel H, Colburn W, Trown P, Merigan T, Dziewanowski Z: Recombinant leukocyte A interferon: Pharmacokinetics, single-dose tolerance, and biological effects in cancer patients. Ann Intern Med 96: 549-556, 1982
8. Janssen HLA, Berk L, Vermeulen M, Schalm SW: Seizures associated with low-dose α-interferon [Letter]. Lancet II: 1580, 1990
9. Bailly F, Mattei A, SiAhmed SN, Trepo C: Uncommon side-effects of interferon. J Viral Hep 4[Suppl 1]: 89-94, 1997
10. Bocci V, Pacini A, Muscettola M, Paulesu L, Pessina GP, Santiano M, Viano I: Renal filtration, absorption and catabolism of human alpha interferon. J Interferon Res 3: 347-352, 1981
11. Bocci V, Pacini A, Muscettola M, Paulesu L, Pessina GP: Renal metabolism of rabbit serum interferon. J Gen Virol 55: 297-304, 1981
12. Tokazewski-Chen SA, Marafino BJ, Stebbing N: Effects of nephrectomy on the pharmacokinetics of various cloned human interferons in the rat. J Pharmacol Exp Ther 227: 9-15, 1983
13. Radvanski E, Perentesis G, Jacobs S, Oden E, Affrime M, Symchowicz, Zampaglione N: Pharmacokinetics of interferon α-2b in healthy volunteers. J Clin Pharmacol 27: 432-435, 1987
14. Hirsch MS, Tolkoff-Rubin NE, Kelly AP, Rubin RH: Pharmacokinetics of human and recombinant leukocyte interferon in patients with chronic renal failure who are undergoing hemodialysis. J Infect Dis 148: 335, 1983
15. Buisson C, Degos F, Daniel F, Dupuy CA, Sari R, Simon N, Lemonnier C, Lebon P, Pasteur Vallery-Radot CH: Pharmacokinetics of alpha interferon-2b in haemodialysis [Abstract]. Nephrol Dial Transplant 9: 977-978, 1994
16. Deleted in proof.
17. Pol S, Thiers V, Carnot F, Zins B, Romeo R, Berthelot P, Bréchet C: Efficacy and tolerance of α-2b interferon therapy on HCV infection of hemodialyzed patients. Kidney Int 47: 1412-1418, 1995
18. Raptopoulou-Gigi M, Spaia S, Garifallos A, Xenou P, Orphanou H, Zarafidou E, Petridou P, Vrettou H, Vagionas G, Galaktidou G, Mavroudi I, Efkarpidou A, Kortsaris A: Interferon-α2b treatment of chronic hepatitis C in hemodialysis patients. Nephrol Dial Transplant 10: 1834-1837, 1995
19. Okuda K, Hayashi H, Yokozeki K, Kondo T, Kashima T, Irie Y: Interferon treatment for chronic hepatitis C in haemodialysis patients: Suggestions based on a small series. J Gastroenterol Hepatol 10: 616-620, 1995
20. Hoofnagle JH, Lau D: Chronic viral hepatitis: Benefits of current therapies. N Engl J Med 334: 1470-1471, 1996
21. Okuda K, Hayashi H, Yokozeki K, Irie Y: Destruction of hepatitis C virus particles by hemodialysis. Lancet 347: 909-910, 1996
22. Poynard T, Leroy V, Cohard M, Mathurin P, Opolon P, Zarski J: Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: Effects of dose and duration. Hepatology 24: 778-789, 1996
23. Hadziyannis SL, Tsantoulas D, Raptopoulou M, Kitis G, Vafiades E, Tassopoulos NC, Areias J, Ma M, Steffen M, Vogel W, Stalgis C, Doran Z, Glue P: Induction dosing with interferon 2b: An international study [Abstract]. Hepatology 26: 420A, 1997
24. Kanai K, Kako M, Kumada T, Tubouchi H, Aikawa T, Kojima M, Harada E, Kawasaki T, Nakajima M, Mishiro S, Mayumi M: Long-term administration of high-dose interferon is effective for chronic hepatitis C-genotype 1b [Abstract]. Hepatology 26: 417A, 1997
25. Hinchey J, Chaves C, Appignani B, Breen J, Pao L, Wang A, Pessin MS, Lamy C, Mas JL, Caplan LR: A reversible posterior leukoencephalopathy syndrome. N Engl J Med 334: 494-500, 1996
26. Edmunds ME, Walls J, Tucker B, Baker LRI, Tomson CRV, Ward M, Cunningham J, Moore R, Winearls CG: Seizures in haemodialysis patients treated with recombinant erythropoietin. Nephrol Dial Transplant 4: 1065-1069, 1989
27. Mamus SW, Oken MM, Zanjani ED: Suppression of normal human erythropoiesis by human recombinant DNA-produced alpha-2 interferon in vitro. Exp Hematol 14: 1015-1022, 1986
28. Silver RT: Interferon-α2b: A new treatment for polycythemia vera. Ann Intern Med 119: 1091-1092, 1993